10-K: Metagenomi's 10-K Filing Reveals Progress in Gene Editing Pipeline, Hemophilia A Program Leads the Way

Metagenomi's 2024 10-K filing highlights advancements in its gene editing platform and progress in its lead Hemophilia A program, with plans for IND filings in 2026.

Summary

• Metagenomi, Inc., a precision genetic medicines company, filed its 10-K report for the fiscal year ended December 31, 2024.
• The company is focused on developing curative therapeutics using its proprietary genome editing toolbox.
• Their lead program targets Hemophilia A, utilizing a novel knock-in approach for Factor VIII (FVIII) expression.
• Data from non-human primate studies demonstrated durable FVIII activity levels over 16.5 months.
• The company plans to complete IND and CTA filings for MGX-001, their Hemophilia A development candidate, in 2026.
• Metagenomi is also advancing therapeutic candidates for secreted protein deficiencies, building on the MGX-001 editing system.
• In collaboration with Ionis Pharmaceuticals, they achieved in vivo proof-of-concept in all four Wave 1 therapeutic targets focused on cardiometabolic diseases.
• The company's technology platform development includes advancements in ultra-small systems and base editors.
• They are expanding their toolbox to include RNA and DNA Mediated Integration Systems.
• The company faces competition from other gene therapy and genome editing companies.
• Metagenomi is also involved in a securities class action lawsuit filed in September 2024.
• As of December 31, 2024, the company had $248.3 million in cash, cash equivalents, and available-for-sale marketable securities.

Sentiment

Score: 6

Explanation: The document presents a balanced view, highlighting both progress and challenges. While there are positive developments in the pipeline, the company's financial situation and competitive landscape introduce uncertainty.

Positives

• Durable FVIII activity achieved in NHPs over 16.5 months in the Hemophilia A program.
• Bioengineered FVIII construct demonstrates significantly higher activity compared to wild type FVIII.
• In vivo proof-of-concept achieved for multiple secreted protein deficiency disorders.
• In vivo rodent proof-of-concept achieved in all four Wave 1 therapeutic targets in the Ionis collaboration.
• SMART nucleases are small enough to fit within an AAV, expanding delivery options.
• ABEs are potentially targetable to over 95% of the human genomes base pairs.
• The company has a broad patent estate protecting its intellectual property.
• The company has a cGMP facility capable of manufacturing clinical grade nucleases and mRNA.

Negatives

• The company has incurred significant losses since inception and expects to incur losses for the foreseeable future.
• The company is very early in its development efforts and has not yet initiated IND-enabling studies or clinical development of any product candidate.
• The company is subject to additional development challenges and risks due to the novel nature of its genome editing technology.
• The company is involved in a securities class action lawsuit.
• The company faces significant competition in an environment of rapid technological change.

Risks

• The company may never achieve or maintain profitability.
• The company's operations will require substantial additional funding.
• The company may be forced to delay, reduce, or terminate certain of its research and product development programs if unable to raise additional capital.
• The company is subject to additional development challenges and risks due to the novel nature of its genome editing technology.
• The company's commercial success depends on its ability to obtain, maintain, enforce, and otherwise protect its intellectual property.
• The impacts of cyber attacks and data privacy breaches on the company's business.

Future Outlook

The company anticipates that its expenses will increase substantially as it continues to invest in research and development activities, conduct clinical trials, and seek regulatory approval for its product candidates.

Management Comments

• The company is taking a stepwise approach deploying its genome editing toolbox to develop potentially curative therapies for patients.
• The company believes its therapeutic programs are well-positioned to leverage the clinical, regulatory, and manufacturing advancements made to date across gene therapy, gene editing, and delivery modalities to accelerate progression to clinical trials and potential approval.

Industry Context

The pharmaceutical and biotechnology industries, including the gene therapy and genome editing fields, are characterized by rapidly advancing technologies, intense competition, and a reliance on strong intellectual property.

Comparison to Industry Standards

• The document mentions several publicly traded companies utilizing CRISPR/Cas nuclease technology, including Caribou Biosciences, Inc., Editas Medicine, Inc., CRISPR Therapeutics AG and Intellia Therapeutics, Inc.
• Beam Therapeutics Inc. and Verve Therapeutics, Inc. utilize base editing technology and Prime Medicine utilizes prime editing technology.
• Several other companies such as Sangamo Therapeutics, Inc., Precision BioSciences, Inc., Cellectis S.A., and bluebird bio, Inc. utilize first-generation nuclease-based genome editing technologies, including ZFNs, engineered meganucleases and TALENs.
• The document also mentions valoctocogene roxaparvovec, the first hemophilia A gene therapy, which was conditionally approved for use in Europe in August 2022 and was approved in the United States in June 2023.

Legal Proceedings

• A class action complaint was filed in the U.S. District Court for the Northern District of California against the company and certain of its officers and certain of its current and former directors, captioned Vreeland v. Metagenomi Inc. et al., No. 5:24-cv-06765 (the Securities Action).
• The Securities Action alleges violations of Section 11 of the Securities Act against all defendants and control person violations of Section 15 against the individuals.
• The Securities Action alleges that the defendants made misleading statements and omitted to disclose material information concerning the company's collaboration with Moderna in the company's registration statement and final prospectus materials filed in January 2024 and February 2024.
• The Securities Action seeks, among other things, compensatory damages as well as costs and expenses, including attorneys fees and expert fees.
• On February 10, 2025, the court appointed Mingxi Bi as lead plaintiff.
• The lead plaintiff's amended complaint is due on April 4, 2025 under the current case schedule.
• The company is currently unable to predict the outcome of this lawsuit and therefore cannot determine the likelihood of loss, if any, nor estimate a range of possible loss.
• The company intends to defend vigorously against this litigation.

Stakeholder Impact

• Shareholders: The company's financial performance and progress in its pipeline will impact shareholder value.
• Employees: The company's ability to attract and retain talent is crucial for its success.
• Patients: The company's development of curative therapies has the potential to improve the lives of patients with genetic diseases.
• Collaborators: The company's collaborations with other companies are important for its research and development efforts.

Next Steps

• Complete IND and CTA filings for MGX-001 in 2026.
• Disclose the lead indication for the secreted protein deficiency platform and achieve NHP proof-of-concept in 2025.
• Nominate a development candidate in a secreted protein deficiency disorder in 2026.
• Nominate one to two development candidates from the Wave 1 targets in the Ionis collaboration in 2025.
• Initiate IND-enabling activities for the development candidates nominated in 2025 and nominate additional development candidates from the remaining Wave 1 targets in 2026.

Key Dates